Theranostics with photodynamic therapy for personalized medicine: to see and to treat.

"Competing Interests: The authors have declared that no competing interest exists."

"This work was financially supported by an ERC Consolidator Grant Photo-MedMet to G. G. (GA 681679), an ANR grant (COSETTE Project) and has received support under the program ''Investissements d'Avenir'' launched by the French Government and implemented by the ANR with the reference ANR-10-IDEX-0001-02 PSL (G. G.). This research was funded in part by the Austrian Science Fund (FWF) [I5721-N to T. LM]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. Y. W. thanks the China Scholarship Council for financial support. Biographies: Youchao WANG obtained her MSc in organic chemistry (2020) at the Technical Institute of Physics and Chemistry, Chinese Academy of Sciences in Beijing. In 2020, she was awarded a China Scholarship Council to carry out her PhD studies under the supervision of Prof. Gilles Gasser at Chimie ParisTech, PSL University. She is currently working on the development of organometallic-based theranostic drugs, which combine photodynamic therapy, nuclear imaging and radiotherapy.: Johannes Nikodemus STAUDINGER obtained his MSc in chemistry (2021) at the University of Vienna. In 2022 he started his PhD studies under the supervision of Prof. Thomas Mindt at the University of Vienna. Currently he is working on the development of new theranostic compounds, which combine nuclear imaging, radiotherapy and photodynamic therapy.: Thomas L. Mindt became Professor in radiopharmaceutical chemistry at the University of Basel (Switzerland) in 2009. In 2016, he moved to Vienna (Austria) as a co-founder of the Ludwig Boltzmann Institute Applied Diagnostics and became Professor in Bioinorganic Radiochemistry at the University of Vienna in 2020. Tom received several fellowships and awards including the Young Investigator Award of the Society of Radiopharmaceutical Sciences and the Max Lüthi Honor of the Swiss Chemical Society. Tom´s research focusses on the use of metallic radioisotopes for diagnostic and therapeutic applications in nuclear medicine.: Gilles Gasser started his independent scientific career at the University of Zurich (Switzerland) in 2010 before moving to Chimie ParisTech, PSL University (Paris, France) in 2016 to take a PSL Chair of Excellence. Gilles was the recipient of several fellowships and awards including the Alfred Werner Award from the Swiss Chemical Society, an ERC Consolidator Grant and Proof of Concept, the European BioInorganic Chemistry (EuroBIC) medal and the Pierre Fabre Award for therapeutic innovation from the French Société de Chimie Thérapeutique. Gilles' research interests lay in the use of metal complexes in different areas of medicinal and biological chemistry."